HEMATOLOGY

During a Targeted Oncology case-based roundtable discussion, Javier Pinilla-Ibarz, MD, PhD, discusses risk factors and prophylactic options for tumor lysis syndrome.

During a Targeted Oncology case-based roundtable event, Rachel B. Salit, MD, discussed the case of a patient with acute graft versus host disease, steroid dependence, and therapy for steroid-refractory disease.

Orphan drug designation has been granted to HT-KIT from the FDA for the treatment of mastocytosis

The phase 3 EQUATOR clinical trial has been initiated in the United States for the treatment of patients with acute graft-versus-host disease.

Jesus Berdeja, MD, shares factors oncologists in the community should consider when referring patients for chimeric antigen receptorT-cell therapy with the newly approved agent ciltacabtagene autoleucel.

John Mascarenhas, MD, provides advice to oncologists on the use of pacritinib to treatment patients with myelofibrosis and severe thrombocytopenia.

In an interview with Targeted Oncology, Ronald Paquette, MD, discussed MDS and what factors may impact the success of a patient’s treatment when undergoing transplant.

John Mascarenhas, MD, discusses the mechanism of action of pacritinib and how it differs from ruxolitinib and fedratinib.

The supplemental new drug application for ibrutinib as a potential treatment for pediatric chronic graft-versus-host disease is supported with findings from the phase 1/2 IMAGINE study.

The treatment and preventive agent landscape for graft-versus-host disease is growing for patients with hematologic malignancies who receive a stem cell transplant.

Srdan Verstovsek, MD, discussed maintaining hematocrit levels in patients with polycythemia vera as well as research on the use of rusfertide.

SWOG 1318 results are promising for extended blinatumomab use in patients with acute lymphoblastic leukemia.

During a Targeted Oncology case-based roundtable event, Uday R. Popat, MD, discussed the approaches to identifying and managing graft-vs-host disease.

Ronald S. Go, MD, explains how toxicities of treatment for histiocytic neoplasms compared with toxicities observed in other malignancies.

Early evidence indicates that iterative detection, profiling, and targeting of minimal residual disease could improve outcomes and even lead to a cure.

An application for approval of a new dosing schedule of Rylaze has been submitted to the FDA.

With a partial clinical hold placed by the FDA, all studies of magrolimab plus azacitidine must halt screening and enrollment.

For the treatment of patients with myelodysplastic syndrome, the FDA has granted an orphan drug designation to eltanexor.

A phase 2b study aims to confirm positive efficacy and safety results previously reported with the combination of maveropepimut-S and pembrolizumab in patients with relapsed or refractory diffuse large B-cell lymphoma.

In an interview with Targeted Oncology, Ronald S. Go, MD, discussed the new guidelines for the diagnosis and treatment of histiocytic neoplasms, challenges with managing the disease, and toxicity management.

Twenty-two days following transplantation, a patient with graft-versus-host disease presented with new symptoms.

Patients with high levels of amphiregulin appeared to be at a higher risk of early death from acute graft-versus-host-disease, signaling that it may be a predictive biomarker.

Although cytokine release syndrome can occur in patients treated with APVO436, the event can be managed with steroids without adversely affecting treatment.

John Allan, MD, looks to the future of chronic lymphocytic leukemia treatments.

An expert describes various treatment approaches for patients with high-risk chronic lymphocytic leukemia.